Your browser doesn't support javascript.
loading
[Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate]. / Respuesta analgésica y efectos secundarios en pacientes con metástasis osteoblásticas tratados con Samario-153 etilendiaminotetrametilenfosfato.
Lovera, C; Massardo, T; Galleguillos, M C; González, P; Comparini, B; Yáñez, M; Fodor, M; Gil, M C; Araya, G; Tomicic, M.
Afiliação
  • Lovera C; Centro de Medicina Nuclear, Hospital Clínico, Universidad de Chile, Santiago, Chile.
Rev Med Chil ; 126(8): 963-71, 1998 Aug.
Article em Es | MEDLINE | ID: mdl-9830748
BACKGROUND: Samarium153 EDTMP, a beta and gamma emitter, is used in the palliative therapy of painful bone metastases. AIM: To evaluate the analgesic effects and myelotoxicity of Samarium153 EDTMP in patients with prostate, breast and renal carcinoma. PATIENTS AND METHODS: Twenty patients with bone metastases (11 males), aged 65 years old as a mean, received a 1 to 2 mCi/kg intravenous dose of Samarium153 EDTMP, produced in Chile. Patients were followed thereafter during 4 to 40 weeks. Pain was assessed using a visual analogue scale. RESULTS: Pain decreased from a score of 6.4 prior to treatment, to 2.7 at the fourth week of therapy and the effect lasted a mean of 12.5 weeks. Myelotoxicity was observed in 68% of cases (WHO stage I in 21%, stage II in 37%, stage III in 11% and no patients in stage IV). Platelets were the most affected series and neutrophils the least affected. Cell counts returned to normal between the sixth and eighth week. Seventy nine percent of patients decreased their basal analgesic therapy at the sixth week and 88% did so at the eighth week. Forty one percent of these patients discontinued all analgesics. CONCLUSIONS: Samarium153 EDTMP is effective in the treatment of pain in patients with bone metastases and its myelotoxicity is low to moderate. It should be considered as a therapy for this type of pain, with the precaution of performing periodical bood counts.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Compostos Organofosforados / Dor / Cuidados Paliativos / Radioisótopos / Medula Óssea / Neoplasias Ósseas / Analgésicos não Narcóticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: Es Revista: Rev Med Chil Ano de publicação: 1998 Tipo de documento: Article País de afiliação: Chile País de publicação: Chile
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Compostos Organofosforados / Dor / Cuidados Paliativos / Radioisótopos / Medula Óssea / Neoplasias Ósseas / Analgésicos não Narcóticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: Es Revista: Rev Med Chil Ano de publicação: 1998 Tipo de documento: Article País de afiliação: Chile País de publicação: Chile